Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report
- PMID: 40276688
- PMCID: PMC12020544
- DOI: 10.1055/a-2558-6468
Preoperative Administration of Amphotericin B in Orbital Mucormycosis Management: A Case Report
Abstract
This case report presents a 29-year-old male with diabetes mellitus who developed rhino-orbito-cerebral mucormycosis (ROCM) that was successfully treated with liposomal amphotericin B orbital injections. Despite emergent endoscopic debridement, the patient's disease progressed intracranially and intraorbitally, but he declined further surgical intervention. Subsequently, due to rapid acute vision loss, we initiated transcutaneous retrobulbar amphotericin B (TRAMB) injections. Following these injections, visual acuity, motility, and intraorbital fungal burden improved despite intracranial progression. This report highlights the benefits of TRAMB administration in aggressive fungal infections and explores the mechanisms behind its effectiveness, particularly in globe preservation. By targeting the infection in an area with a relatively robust blood supply, TRAMB reduces surgical difficulty and improves overall outcomes.
Keywords: TRAMB injections; amphotericin B; antifungal therapy; diabetes mellitus; fungal infection; globe preservation; intracranial extension; minimally invasive treatment; orbital mucormycosis; preoperative management.
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ).
Conflict of interest statement
Conflict of Interest None declared.
Figures




Similar articles
-
Outcomes of transcutaneous retrobulbar Amphotericin B (TRAMB) as an adjuvant therapy for rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19.Int Ophthalmol. 2023 Jun;43(6):1919-1926. doi: 10.1007/s10792-022-02591-0. Epub 2022 Nov 24. Int Ophthalmol. 2023. PMID: 36427099 Free PMC article.
-
Transcutaneous retrobulbar injection of amphotericin B in rhino-orbital-cerebral mucormycosis: a review.Orbit. 2022 Jun;41(3):275-286. doi: 10.1080/01676830.2021.1990351. Epub 2021 Oct 31. Orbit. 2022. PMID: 34720026 Review.
-
Transcutaneous retrobulbar amphotericin B for rhino-orbital-cerebral mucormycosis: a multi-center retrospective comparative study.Orbit. 2024 Feb;43(1):41-48. doi: 10.1080/01676830.2023.2186435. Epub 2023 Mar 7. Orbit. 2024. PMID: 36880205
-
Retrospective analysis of the role of retrobulbar amphotericin-B injection in the management of COVID-19 associated rhino-orbito-cerebral-mucormycosis.Pan Afr Med J. 2022 Aug 25;42:312. doi: 10.11604/pamj.2022.42.312.34757. eCollection 2022. Pan Afr Med J. 2022. PMID: 36451988 Free PMC article.
-
Retrobulbar Injection of Amphotericin B in Patients With COVID-19 Associated Orbital Mucormycosis: A Systematic Review.Ophthalmic Plast Reconstr Surg. 2022 Sep-Oct 01;38(5):425-432. doi: 10.1097/IOP.0000000000002256. Epub 2022 Aug 8. Ophthalmic Plast Reconstr Surg. 2022. PMID: 35943425 Free PMC article.
References
-
- Chakrabarti A, Das A, Mandal J et al.The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(04):335–342. - PubMed
-
- Bhandari J, Thada P K, Nagalli S.Rhinocerebral Mucormycosis. (Updated September 15, 2023)In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Accessed March 25, 2025 at:https://www.ncbi.nlm.nih.gov/books/NBK559288/ - PubMed
-
- Binder U, Maurer E, Lass-Flörl C. Mucormycosis–from the pathogens to the disease. Clin Microbiol Infect. 2014;20 06:60–66. - PubMed
Publication types
LinkOut - more resources
Full Text Sources